Findings of Research Misconduct, 941 [2013-00010]

Download as PDF Federal Register / Vol. 78, No. 4 / Monday, January 7, 2013 / Notices FEDERAL RESERVE SYSTEM DEPARTMENT OF HEALTH AND HUMAN SERVICES Formations of, Acquisitions by, and Mergers of Bank Holding Companies Office of the Secretary The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 31, 2013. A. Federal Reserve Bank of St. Louis (Yvonne Sparks, Community Development Officer) P.O. Box 442, St. Louis, Missouri 63166–2034: 1. Jacksonville Bancorp, Inc., Jacksonville, Illinois; to become a bank holding company through the termination of the election by Jacksonville Savings Bank, Jacksonville, Illinois to be treated as a savings association. wreier-aviles on DSK7SPTVN1PROD with Dated: Board of Governors of the Federal Reserve System, January 2, 2013. Michael J. Lewandowski, Assistant Secretary of the Board. [FR Doc. 2013–00046 Filed 1–4–13; 8:45 am] BILLING CODE 6210–01–P VerDate Mar<15>2010 15:16 Jan 04, 2013 Jkt 229001 Findings of Research Misconduct Office of the Secretary, HHS Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Paul J. Muchowski, Ph.D., The J. David Gladstone Institutes: Based on the report of an investigation conducted by The J. David Gladstone Institutes (Gladstone) and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Paul J. Muchowski, former Senior Investigator, Gladstone Institute of Neurological Disease, Gladstone, engaged in research misconduct in research supported by National Institute of Neurological Diseases and Stroke (NINDS), National Institutes of Health (NIH), grant R01 NS054753–06A1. ORI found that the Respondent engaged in research misconduct by falsifying and fabricating data that was included in one (1) funded NIH grant R01 NS054753–06A1 and two (2) submitted NIH grant applications R01 NS054753–06 and R01 NS047237–06. Specifically, ORI finds that the Respondent knowingly and intentionally: • Falsely reported research experiments when the results did not exist at the time the grant applications were submitted. Specifically: fl in Figures 19–21 and related text of grant application R01 NS047237–06, the Respondent claimed he had successfully transduced human neuroblastoma SH–SY5Y cells expressing a-synuclein (aSyn) with lentiviruses containing small hairpin RNAs (shRNAs) that targeted Cog6, Stx7, Vps52, or Vps33a. The Respondent reported lentiviral expressed Cog6 significantly exacerbated a-Syn toxicity in SH–SY5Y cells, when only plasmid shRNAs were generated and utilized at the time the grant application was submitted. fl in Figure 5 and the accompanying text of grant R01 NS054753–06A1, the Respondent described the insertion of toxic and inert mutant huntingtin (htt) fragments into maltose binding proteinHtt-Cerulean constructs with a nonpathogenic (25Q) or pathogenic (46Q) polyQ repeat, with and without Cerulean. The modified proteins were claimed to have been purified, when the constructs had not been made at the time the grant was submitted. SUMMARY: PO 00000 Frm 00014 Fmt 4703 Sfmt 9990 941 fl in Figures 5 and 6 and the accompanying text of grant R01 NS054753–06A1, the Respondent claimed to have cloned toxic and inert mutant htt fragments into lentiviral constructs and generated lentiviruses, when the constructs were not made. fl in Figure 6 and related text in grant R01 NS054753–06A1, the Respondent claimed to have tested immunoblots of lysates from primary neurons with an antibody against mutant htt, which demonstrated that levels of htt expression in transduced cells were roughly equivalent to levels in normal neurons, when the experiment was not conducted. • Falsified Figure 3 of grant application R01 NS054753–06 by labeling the Western blot images for the expression of mutant htt in lentiviraltransduced primary neurons as ‘Cortex’ (left panel) and ‘Striatum’ (right panel), when the results were actually from the microglial cell lines N9 and BV2, respectively. Dr. Muchowski has entered into a Voluntary Settlement Agreement and has voluntarily agreed for a period of two (2) years, beginning on December 10, 2012: (1) To have his research supervised; Respondent agreed that prior to the submission of an application for PHS support for a research project on which his participation is proposed and prior to his participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of his duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of his research contribution; he agreed that he shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; and (2) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200. David E. Wright, Director, Office of Research Integrity. [FR Doc. 2013–00010 Filed 1–4–13; 8:45 am] BILLING CODE 4150–31–P E:\FR\FM\07JAN1.SGM 07JAN1

Agencies

[Federal Register Volume 78, Number 4 (Monday, January 7, 2013)]
[Notices]
[Page 941]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-00010]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Paul J. Muchowski, Ph.D., The J. David Gladstone Institutes: Based 
on the report of an investigation conducted by The J. David Gladstone 
Institutes (Gladstone) and additional analysis conducted by ORI in its 
oversight review, ORI found that Dr. Paul J. Muchowski, former Senior 
Investigator, Gladstone Institute of Neurological Disease, Gladstone, 
engaged in research misconduct in research supported by National 
Institute of Neurological Diseases and Stroke (NINDS), National 
Institutes of Health (NIH), grant R01 NS054753-06A1.
    ORI found that the Respondent engaged in research misconduct by 
falsifying and fabricating data that was included in one (1) funded NIH 
grant R01 NS054753-06A1 and two (2) submitted NIH grant applications 
R01 NS054753-06 and R01 NS047237-06.
    Specifically, ORI finds that the Respondent knowingly and 
intentionally:
     Falsely reported research experiments when the results did 
not exist at the time the grant applications were submitted. 
Specifically:
    [rtrif] in Figures 19-21 and related text of grant application R01 
NS047237-06, the Respondent claimed he had successfully transduced 
human neuroblastoma SH-SY5Y cells expressing [alpha]-synuclein 
([alpha]Syn) with lentiviruses containing small hairpin RNAs (shRNAs) 
that targeted Cog6, Stx7, Vps52, or Vps33a. The Respondent reported 
lentiviral expressed Cog6 significantly exacerbated [alpha]-Syn 
toxicity in SH-SY5Y cells, when only plasmid shRNAs were generated and 
utilized at the time the grant application was submitted.
    [rtrif] in Figure 5 and the accompanying text of grant R01 
NS054753-06A1, the Respondent described the insertion of toxic and 
inert mutant huntingtin (htt) fragments into maltose binding protein-
Htt-Cerulean constructs with a nonpathogenic (25Q) or pathogenic (46Q) 
polyQ repeat, with and without Cerulean. The modified proteins were 
claimed to have been purified, when the constructs had not been made at 
the time the grant was submitted.
    [rtrif] in Figures 5 and 6 and the accompanying text of grant R01 
NS054753-06A1, the Respondent claimed to have cloned toxic and inert 
mutant htt fragments into lentiviral constructs and generated 
lentiviruses, when the constructs were not made.
    [rtrif] in Figure 6 and related text in grant R01 NS054753-06A1, 
the Respondent claimed to have tested immunoblots of lysates from 
primary neurons with an antibody against mutant htt, which demonstrated 
that levels of htt expression in transduced cells were roughly 
equivalent to levels in normal neurons, when the experiment was not 
conducted.
     Falsified Figure 3 of grant application R01 NS054753-06 by 
labeling the Western blot images for the expression of mutant htt in 
lentiviral-transduced primary neurons as `Cortex' (left panel) and 
`Striatum' (right panel), when the results were actually from the 
microglial cell lines N9 and BV2, respectively.
    Dr. Muchowski has entered into a Voluntary Settlement Agreement and 
has voluntarily agreed for a period of two (2) years, beginning on 
December 10, 2012:
    (1) To have his research supervised; Respondent agreed that prior 
to the submission of an application for PHS support for a research 
project on which his participation is proposed and prior to his 
participation in any capacity on PHS-supported research, Respondent 
shall ensure that a plan for supervision of his duties is submitted to 
ORI for approval; the supervision plan must be designed to ensure the 
scientific integrity of his research contribution; he agreed that he 
shall not participate in any PHS-supported research until such a 
supervision plan is submitted to and approved by ORI; Respondent agreed 
to maintain responsibility for compliance with the agreed upon 
supervision plan; and
    (2) to exclude himself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant.

FOR FURTHER INFORMATION CONTACT: Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8200.

David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2013-00010 Filed 1-4-13; 8:45 am]
BILLING CODE 4150-31-P